We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Risk Factors Associated with Lou Gehrig's Disease

By Biotechdaily staff writers
Posted on 17 Apr 2007
Thirty-four unique variations in the human genetic code were identified and may explain the underlying factors that contribute to amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. More...


Under the direction of John Hardy, Ph.D. and Bryan Traynor, M.D., from the U.S. National Institute on Aging's Laboratory of Neurogenetics (Bethesda, MD, USA) and the Section on Developmental Genetic Epidemiology, U.S. National Institute of Mental Health (Bethesda, MD, USA), Illumina's (San Diego, CA, USA) HumanHap550 BeadChip was used to produce more than 300 million genotypes in a search for those single nucleotide polymorphisms (SNPs) that increase risk for ALS. ALS fatally attacks 10,000 Americans each year with an estimated one in 1,000 people is at risk of developing the disease.

A key goal of our product development efforts is to provide backwards compatibility for our customers. This means that as we develop new generations of products, current customers have the seamless ability to achieve the same level of content as found on the new BeadChip, said Carsten Rosenow, DNA analysis marketing manager. For example the HumanHap240S and HumanHap450S BeadChips give researchers the opportunity to upgrade from the HumanHap300 and HumanHap550 respectively, obtaining the same level of content as found on the HumanHap550 and Human 1M.

We recognize the importance of developing technologies that are powerful and scalable, and that deliver industry-leading value that enable users to find the answers they need. The Lou Gehrig's disease studies are an example of how our tools are being used to accelerate the discovery of association markers for complex disease, said Jay Flatley, president and CEO of Illumina.

The HumanHap240S Genotyping BeadChip contains 240,000 tag SNPs derived from the phase I and II HapMap data, and provides tag SNP coverage in regions of lower linkage disequilibrium in the genome. The addition of the HumanHap240S to the HumanHap300, which contains 317,000 tagSNPs derived from the phase I HapMap data, provides the same level of comprehensive genomic coverage across multiple populations as found on the HumanHap550.

All three BeadChips are powered by the Infinium assay, which enables intelligent SNP selection utilizing tagSNPs. The HumanHap300 is now available in a two-sample BeadChip (HumanHap300-Duo) and can be customized with up to 60,800 additional custom Beadtypes (HumanHap300-Duo+). The HumanHap550 can also be customized with up to 121,600 additional Beadtypes (HumanHap500+).

The study was published in the journal Lancet Neurology on March 12, 2007.


Related Links:
Institute of Aging
National Institute of Mental Health
Illumina

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.